Had an amazing time listening, learning and presenting at #TTLC24 Elsa Anagnostou

Final day of #TTLC24 Fairmont Miramar!

Jill Feldman Eric K. Singhi, MD Fawzi Abu Rous, MD Aakash Desai, MD, MPH IASLC

Dr. Angel Qin discusses targeted perioperative therapies in #nsclc . Lots of new agents building on success in EGFR and ALK studies to date. #TTLC24

So fun to have had the opportunity to bond with mentors! #TTLC24

Team LungCancerRx 🫁💊 representing at #TTLC24 !

What’s your favorite moment of the conference so far? Eric K. Singhi, MD Aakash Desai, MD, MPH Fawzi Abu Rous, MD Stephen V Liu, MD Narjust Florez, MD, FASCO Charu Aggarwal, MD, MPH, FASCO Lecia Sequist, MD, MPH Dr. Estela Rodriguez Balazs Halmos IASLC

our ROS RET NTRK rountable at the IASLC #TTLC24 great talks from JessicaJLinMD Misako Nagasaka Debora Bruno, MD with LudaBazhenovaMD Narjust Florez, MD, FASCO Rajat Thawani wnd others!

Such a great experience to be able to serve as a speaker at #TTLC24 . The first time I came to this meeting was in 2016 when I was a volunteer at UCLA. It seems like a dream come true to come as an onc fellow.

Gathering with great friends at #TTLC24 ! ⁦Drew Moghanaki 🐕⁩ ⁦Jeff Bradley, MD⁩ ⁦.⁩ ⁦Memorial Sloan Kettering Cancer Center⁩ ⁦Penn Medicine - Abramson Cancer Center⁩ ⁦Piedmont⁩ Oncology ⁦IASLC⁩

Had a great time discussing our work looking at outcomes in patients with #EGFR exon 19 deletion or L858R mutated #lungcancer post-progression on osimertinib by mechanism of resistance at the #TTLC24 poster session!

Approved RET inhibitors in NSCLC include selpercatinib, pralsetinib. Mechanisms of resistance are diverse after current RETi. Several next gen RETi under development. Selpercatinib is also being evaluated in early stage disease. Wonderful talk by Dr. Jyoti Patel. #TTLC24

Interesting and much-needed efforts by ⁦National Cancer Institute⁩ to modernize clinical trials presented by Dr. Prindiville at #TTLC24 - 1.make data collection less onerous, 2.increase workforce diversity, 3.implement virtual programs to mitigate staffing shortages

LOVE getting to dive deep into all the #newdata at #TTLC24 with my AMAZING Thoracic Onc PharmD & #NGS 🧬 specialist Dr. Mya Tran @MyaTranPreciGen!

⬆️⬆️⬆️ give her a follow 👍 on Twitter

#SCLC #LCSM IASLC

#TTLC24 ⁦IASLC⁩ ⁦Chris Draft⁩ ⁦Jennifer C. King, PhD⁩ Last Day

The pace of drug development for ALK-fusion positive NSCLC has been one of the fastest. Prelim results of NVL-655, 4th gen ALK TKI, are promising. What characteristics should a hypothetical 5G agent have? Fascinating talk by Dr. Misako Nagasaka #TTLC24

Honored to co-chair the #immunotherapy session with the incredible Dr. Eddie Garon at UCLA this morning at IASLC #TTLC24

Top QAs discussed:
🚨Approach to brain Mets with #IO
🚨How to treat PD-L1 negative dx
🚨Combos w/ TKIs & ADCs

#LCSM #SCLC #NSCLC #nothingsmallaboutit

See the latest evidence supporting #immunotherapy treatments in metastatic, stage III unresectable & stage I-III resectable #NSCLC in this new #MedEd video from #TTLC24 featuring #LungCancer experts Drs. Patel (Sandip Patel MD), Cascone & Heymach: bit.ly/48ImRrc

Thanks for the company during #TTLC24 Eric K. Singhi, MD So happy to call you friend 🫶🏼

Classic #TTLC24 IASLC. Who are your top 10 favorite audience questioners?

#TTLC24 is dense…so much info!

Attendees at 8AM today
…and by 5:30PM

A nuanced + thoughtful discussion by JessicaJLinMD re: what can/can’t be generalized from adjuvant TKI trials—can ADAURA/ALINA be extended to other oncogene-driven NSCLC? Conceptually, yes. But we need more work to delineate specific tox profiles to best counsel our pts. #TTLC24